Despite growing enthusiasm for this minimally invasive option for some men with prostate cancer, focal therapy is still not FDA-approved for prostate cancer and comes with high out-of-pocket costs.

Related Keywords

Maryland , United States , Baltimore , Florida , University Of Chicago , Illinois , The Cleveland Clinic , Ohio , Leesburg , Chicago , Norway , Cleveland , United Kingdom , Cleveland Clinic , Bahamas , The , London , City Of , American , Sloan Kettering , Marvin George , Hashim Ahmed , William Catalona , Daniel Spratt , Jonathan Shoag , University Hospitals Seidman Cancer Center , University Hospitals , Case Western Reserve University In Cleveland , Northwestern University Feinberg School Of Medicine , Imperial College London , Aetna , American Urological Association , Johns Hopkins School Of Medicine , Case Western Reserve University School Of Medicine , Richard Lafrate , Mayo Clinic , Memorial Sloan Kettering , Blue Cross Shield , Case Western Reserve University , Case Western Reserve University School , Johns Hopkins School , Northwestern University Feinberg School , Prostate Carcinoma , Alignant Prostate Neoplasm , Prostate Cancer , Ancer Of The Prostate , Cancer , Alignant Neoplasia , Arcinoma , Alignant Neoplasm , Prostatic , Metastasis , Etastatic Carcinoma , Metastatic Cancer , Metastases , Biologic Therapy , Iologics , Prostate Specific Antigen , Sa , Sa Prostate Specific Antigen , Ultrasonography , Ultrasound , Monogram , Clinical Guidelines , Guidelines ,